Advertisement

Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer

      Abstract

      Metastatic HER2-positive (HER2+) and triple-negative breast cancer (TNBC) confer a 30% or higher risk of developing brain metastases (BrM), but BrM is typically an exclusion criteria for clinical trials, which limits the generalizability of trial results to these patients. We therefore analysed trends in the enrollment of patients with BrM, as well as the use of outcomes specific to the central nervous system (CNS), in phase III clinical trials evaluating systemic therapy for patients with advanced HER2+ and/or TNBC. Notably, 10 of the 34 trials (29%, 95% confidence interval = 15.1%-47.5%) evaluated CNS-specific outcomes and trials that completely excluded patients with BrM were significantly less likely to meet their primary endpoint (n = 6/17, 35%) than those that permitted conditional enrollment (n = 13/15, 87%) (P = .005), suggesting that enrollment of patients with BrM is not detrimental to trial success.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2019.
        CA A Cancer J Clin. 2019; 69: 7-34
        • Kuksis M.
        • Gao Y.
        • Tran W.
        • et al.
        The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
        Neuro Oncol. 2021; 23: 894-904
        • Abrey L.E.
        Inclusion of patients with brain metastases in clinical trials.
        Clin Investig. 2011; 1: 1065-1068
        • Chamberlain M.C.
        • Baik C.S.
        • Gadi V.K.
        • Bhatia S.
        • Chow L.Q.M
        Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma.
        NEUONC. 2017; 19: i1-i24
        • Lin N.U.
        • Prowell T.
        • Tan A.R.
        • et al.
        Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group.
        JCO. 2017; 35: 3760-3773
        • Valiente M.
        • Ahluwalia M.
        • Boire A.
        • et al.
        The evolving landscape of brain metastasis.
        Trends Cancer. 2018; 4: 176-196
        • Corbett K.
        • Sharma A.
        • Pond G.R.
        • et al.
        Central nervous system–specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung cancer, and melanoma.
        JAMA Oncol. 2021; 7: 1062
        • Brufsky A
        • Tiangco B
        • Dakhil S
        • et al.
        Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.
        Breast Cancer Res Treat. 2012; 133
        • Patel R.R.
        • Verma V
        • Miller A.B.
        • et al.
        Exclusion of patients with brain metastases from cancer clinical trials.
        Neuro-Oncol. 2020; 22: 577-579
        • Kim E.S.
        • Bruinooge S.S.
        • Roberts S
        • et al.
        Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
        JCO. 2017; 35: 3737-3744
        • Soffietti R.
        • Chiavazza C.
        • Rudà R.
        Imaging and clinical end points in brain metastases trials.
        CNS Oncol. 2017; 6: 243-246
        • Brown P.D.
        • Ballman K.V.
        • Cerhan J.H.
        • et al.
        Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1049-1060
        • Brown P.D.
        • Jaeckle K
        • Ballman K.V.
        • et al.
        Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial.
        JAMA. 2016; 316: 401
        • Chang E.L.
        • Wefel J.S.
        • Hess K.R.
        • et al.
        Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial.
        Lancet Oncol. 2009; 10: 1037-1044
        • Brown P.D.
        • Gondi V
        • Pugh S
        • et al.
        Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III Trial NRG oncology CC001.
        JCO. 2020; 38: 1019-1029